Close this search box.

Verve promotes Lister to CSO

ARTICLE | Management Tracks

Plus: Quantum-Si appoints Kummeth independent chair and updates from Alkeus and SAB

By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst

June 1, 2024 12:47 AM UTC

Verve Therapeutics Inc. (NASDAQ:VERV) promoted Troy Lister to CSO from SVP, research and early development, effective June 21. Lister succeeds CSO Andrew Bellinger, who will become an adviser to the gene editing company. Bellinger paid tribute to Verve and its employees in a LinkedIn post, writing, “at Verve, we created an environment where problem solving happened independently from the bottom up.”

Proteomics company Quantum-Si Inc. (NASDAQ:QSI) appointed Charles Kummeth independent chair. Kummeth was president and CEO of Bio-Techne Corp. (NASDAQ:TECH) for over a decade, until February. …